InvVax, Inc.

InvVax is a vaccine development company. Our initial product is a universal influenza vaccine that will disrupt the $5.8 billion global flu vaccine market.

  • Stage Product In Development
  • Industry Biotechnology
  • Location Pasadena, CA, USA
  • Currency USD
  • Founded January 2013
  • Employees 1
  • Incorporation Type C-corp
  • Website inv-vax.com

Company Summary

InvVax is commercializing the world's first universal influenza vaccine. Using next generation sequencing, we determined the effect on viral replication of mutations at all 13,000+ bases in the viral genome. Cross-referencing this with known flu epitopes, we derived a list of 15 “invariant” peptides that cannot be mutated, which are ideal targets for a durable influenza vaccine.

Team

  • Arthur Young
    Founder, Interim CEO

    Earned a PhD from Washington University in St. Louis. He did two post-docs at Harvard and one at UCLA, where he invented InvVax’s core technology. He left academia in 2013 to dedicate 100% of his time to InvVax.

Advisors

Starting a startup?

Join the world's largest startup network for guidance, tools, and fundraising opportunities.

Get Started for Free